AbbVie (NYSE:ABBV) Stock Falls 1% - What's Next?

Key Points

• AbbVie shares fell 1% to $285.88, with trading volume 16% below its average.
• The company raised its 2026 adjusted EPS and revenue outlook, supported by Skyrizi and Rinvoq offsetting Humira’s decline. However, its fourth-quarter adjusted EPS guidance came in below analysts’ consensus.
• Analysts maintain a Moderate Buy consensus and an average price target of $294.67; AbbVie also increased its quarterly dividend from $1.73 to $1.82 per share.

AbbVie Inc. (NYSE:ABBV - Get Free Report) shares were down 1% during trading on Tuesday. The stock traded as low as $284.70 and last traded at $285.88. 5,336,668 shares were traded during mid-day trading, a decline of 16% from the average session volume of 6,328,662 shares. The stock had previously closed at $288.84.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 guidance to adjusted EPS of $13.95–$13.99 and revenue of $67.8 billion, both modestly above prior expectations. Strong performance from newer immunology medicines, including Skyrizi and Rinvoq, has helped offset Humira’s decline. Article: ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: A global licensing agreement with Brise Pharmaceuticals adds a next-generation migraine candidate to AbbVie’s pipeline; the deal could be worth as much as $757 million. Analysts also raised price targets following the company’s quarterly results, reflecting optimism about its growth transition. Article: AbbVie License Deal With Brise Potentially Valued at $757 Million Article: Analysts Increase Their Forecasts on AbbVie
• Neutral Sentiment: Allergan Aesthetics plans to present research at the ASDS 2026 meeting, including data on aesthetic treatments following medical weight loss. The update signals continued investment in the business but does not indicate an immediate change to earnings. Article: Allergan Aesthetics to Present New Research at ASDS 2026
• Negative Sentiment: AbbVie’s fourth-quarter adjusted EPS guidance of $3.83–$3.87 is below the $3.89 consensus estimate, despite revenue guidance slightly above expectations. Commentary also flags a potentially stretched valuation after a strong year, which could make the shares more sensitive to any growth disappointment. Article: AbbVie Hit a New High After Earnings. There’s More Upside Left.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. UBS Group increased their price objective on shares of AbbVie from $275.00 to $295.00 and gave the stock a "neutral" rating in a report on Monday. The Goldman Sachs Group upped their price target on shares of AbbVie from $258.00 to $294.00 and gave the stock a "neutral" rating in a research report on Friday, October 23rd. Guggenheim increased their price target on shares of AbbVie from $288.00 to $322.00 and gave the stock a "buy" rating in a research note on Monday. BNP Paribas Exane lifted their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Finally, Argus upped their price objective on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $294.67.

AbbVie Stock Performance

The firm has a market cap of $505.09 billion, a PE ratio of 49.20, a PEG ratio of 1.31 and a beta of 0.24. The stock has a fifty day moving average price of $269.81 and a 200-day moving average price of $237.57.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.86 earnings per share. As a group, equities analysts predict that AbbVie Inc. will post 13.92 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie's previous quarterly dividend of $1.73. AbbVie's dividend payout ratio (DPR) is presently 119.10%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Burk Holdings LLC purchased a new position in shares of AbbVie in the second quarter valued at $30,000. Marquette Asset Management LLC boosted its holdings in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after buying an additional 48 shares during the period. IMG Wealth Management Inc. grew its holdings in shares of AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after purchasing an additional 153 shares during the last quarter. Principia Wealth Advisory LLC raised its position in shares of AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Tacita Capital Inc acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $42,000. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.